A 9 year old boy with acute lymphoblastic leukemia (ALL) received recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) and showed a marked increment of myeloblasts in the peripheral blood. He was administered repeated courses of intermediate‐dose cytosine arabinoside (Ara‐C) therapy (1500 mg/m2, days 1–5) for frequent central nervous system (CNS) relapse of ALL. The peripheral white blood cell nadir was less than 1000/μL, so he was treated with rhG‐CSF. A marked increment of peripheral blood blasts was noted 3–5 days after rhG‐CSF treatment. These cells decreased with the appearance of mature myeloid cells and disappeared about 2 weeks after the start of treatment. These findings suggested that the blasts might have the ability to differentiate into mature myeloid cells. A control patient with repeated CNS relapse of ALL showed no increment of peripheral blood blasts after similar repeated courses of Ara‐C without rhG‐CSF treatment. Cultured peripheral blood blasts obtained from the present patient showed differentiation into mature myeloid cells by morphological studies and surface marker analysis. These findings indicate that the peripheral blood blasts drawn by G‐CSF were not leukemic blasts but normal myeloblasts.
Although not always susceptible to bacterial infections, low levels of IgG2 were frequently observed in patients with chronic active EBV infection and elevated IgG1 is responsible for the increase of serum IgG in these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.